Treatment with crizotinib has shown efficacy in a variety of ALK mutant and rearranged tumors including non‐small‐cell lung cancer (NSCLC), inflammatory myofibroblastic tumors, and neuroblastoma,8, 9, 10 and now, there is emerging evidence of the effectiveness of ALK inhibitors in the treatment of tumors with ALK overexpression without mutation or fusion.11, 12. The gene discussed is ALK; the disease is inflammatory myofibroblastic tumor.